News aggregator

WADENA, Minn. – A 76-year-old man in need of diabetes medication went missing here Monday morning, authorities say.

A recent study has found that the newer hemoglobin A1C blood test is better than a fasting blood glucose test at predicting a person's future risk of heart disease and stroke.

According to a new Harvard study, it's eating processed meat--not unprocessed red meat--that increases a person's risk of developing heart disease and diabetes.

When some people learn they have diabetes, their first treatment response involves willpower instead of medication. That’s a bad idea for people living with type 2 diabetes, say Kaiser Permanente researchers.

The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a Kaiser Permanente study published in the March issue of Diabetes Care, a journal of the American Diabetes Association. The study found that metformin, an inexpensive, generic drug that helps patients prevent dangerously high blood sugar levels, worked nearly twice as long for people who ...

When Sarah Bouvier of South Burlington was 5 years old, she was diagnosed with Type 1 diabetes, catapulting her into a regimen of insulin injections and strict eating routines.

Art Smith is justifiably proud of his recent 90-pound weight-loss and healthy new regimen that includes one hour of daily exercise.But local endocrinologists, who specialize in treating Type 2 diabetes, disagree with the assertion on the Feb. 4 " Oprah Winfrey " program dedicated to raising awareness of the disease, that he has "reversed" his Type 2 diabetes through diet and exercise alone."He ...

The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a Kaiser Permanente study published in the March issue of Diabetes Care, a journal of the American Diabetes Association.

The January 2010 issue of Roger Gadsby's "Interesting new papers" series is now available.

TREDYFFRIN -- If all of the people in the world who have diabetes gathered under one flag, it would be the fourth-largest country in the world.

Diamyd Medical announces today that one hundred study participants have been included in the ongoing US Phase III study, DiaPrevent. The global Phase III program with the company’s lead drug candidate Diamyd® has thereby enrolled more than 430 children newly diagnosed with type 1 diabetes in Europe and the USA.

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus” trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular ...

PORTLAND, Ore., March 9 (UPI) -- The sooner people with diabetes take the generic drug Metformin that helps prevent high blood sugar levels, the longer it is effective, U.S. researchers said.

One drink a day may help women avoid weight gain, a new study has found.

Report from the National Heart Forum Modelling Team including predictions for the burden of diseases attributable to obesity including diabetes, published 17th February 2010.

Recent guideline from the IDF on SMBG, published in 2009.

The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a new study.

Recent guideline on oral health form the IDF and the World Dental Federation, published in September 2009.

Recently published guideline from the International Diabetes Federation (IDF), published September 2009.

AbstractObjective:

Sulfonylureas have historically been analyzed as a medication class, which may be inappropriate given the differences in properties inherent to the individual sulfonylureas: hypoglycemic risk, sulfonylurea receptor selectivity and effects on myocardial ischemic preconditioning. The purpose of this study was to assess the relationship of individual sulfonylureas and the risk of overall mortality in a large cohort of patients with type 2 diabetes.

Research Design and Methods:

A retrospective cohort study was conducted using an academic health center enterprise-wide electronic health record (EHR) system to identify 11,141 patients with type 2 diabetes (4,279 initiators of monotherapy with glyburide, 4,325 initiators of monotherapy with glipizide, and 2,537 initiators of monotherapy with glimepiride), ≥ 18 years of age, with and without a history of coronary artery disease (CAD), and not on insulin or a non-insulin injectable at baseline. The patients were followed for mortality by documentation in the EHR and Social Security Death Index. Multivariable Cox models were used to compare cohorts.

Results:

No statistically significant difference in the risk of overall mortality was observed among these agents in the entire cohort, but we did find evidence of a trend towards an increased overall mortality risk with glyburide vs. glimepiride (HR 1.36; CI 0.96-1.91) and glipizide vs. glimepiride (HR 1.39; 95% CI 0.99-1.96), in those with documented CAD.

Conclusions:

Our results did not identify an increased mortality risk among the individual sulfonylureas but did suggest that glimepiride may be the preferred sulfonylurea in those with underlying CAD.